Compare Hormel Foods Corp (HRL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs TG Therapeutics Inc — how do they compare? Hormel Foods Corp trades at $24.5 (market cap $13.37B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Hormel Foods Corp is the larger of the two by market cap, and Hormel Foods Corp pays a 4.81% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRL | TGTX | |
|---|---|---|
Market Cap | $13.37B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $29.25 | $59.06 |
52-Week Low | $19.74 | $26.94 |
Enterprise Value | $15.37B | $7.84B |
Dividend Yield | 4.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $24.41, down 1.21% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 28.6x and modest 3.8% net margin, while revenue has been stable around $12B annually. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
HRL offers defensive appeal with consistent dividends and a 4.6% yield, but faces margin pressure and modest growth prospects. Analyst consensus is Hold with a $26.33 price target, suggesting limited upside. Key risks include consumer spending sensitivity and execution challenges under new leadership.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
